Cargando…

Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies

Antiphospholipid syndrome (APS) is an adquired autoimmune pro-thrombotic disease characterized by arterial and/or venous thrombosis and/or fetal losses associated with the persistent presence of antiphospholipid antibodies (aPL) detectable by solid phase assays (anticardiolipin (aCL) and anti-β2 gly...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez-Puerta, José A., Espinosa, Gerard, Cervera, Ricard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698865/
https://www.ncbi.nlm.nih.gov/pubmed/31557999
http://dx.doi.org/10.3390/antib5030018
_version_ 1783444631116054528
author Gómez-Puerta, José A.
Espinosa, Gerard
Cervera, Ricard
author_facet Gómez-Puerta, José A.
Espinosa, Gerard
Cervera, Ricard
author_sort Gómez-Puerta, José A.
collection PubMed
description Antiphospholipid syndrome (APS) is an adquired autoimmune pro-thrombotic disease characterized by arterial and/or venous thrombosis and/or fetal losses associated with the persistent presence of antiphospholipid antibodies (aPL) detectable by solid phase assays (anticardiolipin (aCL) and anti-β2 glycoprotein I, β2GPI) and/or functional coagulation test (lupus anticoagulant (LA)). Most patients with typical APS manifestations have the presence of one or more of conventional aPL, but, some patients might exhibit clinical features related with APS but with persistent negative determinations of “classic” aPL (seronegative APS). Expanding the network of autoantibodies in patients highly suspected of having APS but who have normal results from a conventional test using new antibodies (i.e., phosphatidylserine/prothrombin and β2GPI domain 1) would increase the diagnosis. Thrombosis is one of the leading causes of death among patients with cancer, representing up to 15% of all deaths. Cancer increases the risk of thrombosis and chemotherapy is further associated with a higher risk of thrombosis. In addition, aPL may contribute to an increased risk of thrombosis in patients with malignancies, although the levels do not seem to reflect their pathogenicity. Several malignancies, particularly hematological and lymphoproliferative malignancies, may indeed be associated with the generation of aPL but do not necessarily enhance the thrombophilic risk in these patients.
format Online
Article
Text
id pubmed-6698865
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66988652019-09-05 Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies Gómez-Puerta, José A. Espinosa, Gerard Cervera, Ricard Antibodies (Basel) Review Antiphospholipid syndrome (APS) is an adquired autoimmune pro-thrombotic disease characterized by arterial and/or venous thrombosis and/or fetal losses associated with the persistent presence of antiphospholipid antibodies (aPL) detectable by solid phase assays (anticardiolipin (aCL) and anti-β2 glycoprotein I, β2GPI) and/or functional coagulation test (lupus anticoagulant (LA)). Most patients with typical APS manifestations have the presence of one or more of conventional aPL, but, some patients might exhibit clinical features related with APS but with persistent negative determinations of “classic” aPL (seronegative APS). Expanding the network of autoantibodies in patients highly suspected of having APS but who have normal results from a conventional test using new antibodies (i.e., phosphatidylserine/prothrombin and β2GPI domain 1) would increase the diagnosis. Thrombosis is one of the leading causes of death among patients with cancer, representing up to 15% of all deaths. Cancer increases the risk of thrombosis and chemotherapy is further associated with a higher risk of thrombosis. In addition, aPL may contribute to an increased risk of thrombosis in patients with malignancies, although the levels do not seem to reflect their pathogenicity. Several malignancies, particularly hematological and lymphoproliferative malignancies, may indeed be associated with the generation of aPL but do not necessarily enhance the thrombophilic risk in these patients. MDPI 2016-08-02 /pmc/articles/PMC6698865/ /pubmed/31557999 http://dx.doi.org/10.3390/antib5030018 Text en © 2016 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gómez-Puerta, José A.
Espinosa, Gerard
Cervera, Ricard
Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies
title Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies
title_full Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies
title_fullStr Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies
title_full_unstemmed Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies
title_short Antiphospholipid Antibodies: From General Concepts to Its Relation with Malignancies
title_sort antiphospholipid antibodies: from general concepts to its relation with malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698865/
https://www.ncbi.nlm.nih.gov/pubmed/31557999
http://dx.doi.org/10.3390/antib5030018
work_keys_str_mv AT gomezpuertajosea antiphospholipidantibodiesfromgeneralconceptstoitsrelationwithmalignancies
AT espinosagerard antiphospholipidantibodiesfromgeneralconceptstoitsrelationwithmalignancies
AT cerveraricard antiphospholipidantibodiesfromgeneralconceptstoitsrelationwithmalignancies